LEADER 04224nam 2200589 450 001 9910830823403321 005 20230808191821.0 010 $a1-118-92497-5 010 $a1-118-92493-2 010 $a1-118-92495-9 035 $a(CKB)3710000000603859 035 $a(EBL)4413723 035 $a(SSID)ssj0001622845 035 $a(PQKBManifestationID)16359288 035 $a(PQKBTitleCode)TC0001622845 035 $a(PQKBWorkID)14807818 035 $a(PQKB)11192988 035 $a(PQKBManifestationID)16162274 035 $a(PQKBWorkID)14807819 035 $a(PQKB)24318643 035 $a(MiAaPQ)EBC4413723 035 $a(DLC) 2015041033 035 $a(EXLCZ)993710000000603859 100 $a20151016d2016 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical dilemmas in non-alcoholic fatty liver disease /$fedited by Roger Williams, Simon D. Taylor-Robinson 210 1$aChichester, West Sussex ;$aHoboken, NJ :$cWiley Blackwell,$d2016. 215 $a1 online resource (423 p.) 225 1 $aClinical Dilemmas (UK) 300 $aDescription based upon print version of record. 311 $a1-118-91203-9 320 $aIncludes bibliographical references and index. 327 $aHype or harm from fatty liver disease? / Stephen H Caldwell and Curt Argo -- Worldwide problem / Geoffrey Farrell and Philip Newsome -- Is insulin resistance the key motive for NAFLD? / Desmond Johnston -- Progression to cirrhosis is more likely in children with NAFLD? / Anil Dhawan -- NAFLD as cause of cryptogenic cirrhosis? / Jay Lefkowitch -- Is NAFLD different in absence of metabolic syndrome? / Yusuf Yilmaz -- Occurrence of noncirrhotic HCC in NAFLD / Stephen Harrison and Dawn Torres -- Fibrosis progression molecular pathways all important? / Anna-Mae Diehl and Dr Wing-Kin Syn -- Can fatty liver of NAFLD be distinguished from that of alcoholic liver disease? / David Kleiner and Elizabeth Brunt -- Are inflammasomes and intestinal microbiota relevant in disease progression to NASH? / M. Bilal Siddiqui, M. Shadab Siddiqui and Arun Sanyal -- Can genetic influence in non-alcoholic fatty liver disease be ignored? / Quentin Anstee -- Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? / Soo Lim -- Is there a best method for diagnosis of NAFLD? / Vlad Ratziu -- Choice of non-invasive blood tests and FibroScan / Massimo Pinzani and Manolis Tsocatzis -- Are the guidelines AASLD, IASL, EASL and BSG of help? / Jean-Francois Dufour -- How to choose from different imaging modalities and screening techniques / Hero Hussain -- Are the pros outweighed by the cons of obtaining a liver biopsy? / Simon Taylor-Robinson and Jeremy Cobbold -- Screening for NAFLD in high risk population / Nader Lessan -- Balancing calorie restriction, exercise and weight reduction / Nicholas Finer -- Should physicians be prescribing, or patients self-medicating with Orlistat, vitamin E, vitamin D, insulin antagonist, Trental and coffee? / Brent Neuschwander-Tetri and Haripriya Maddur -- Does improvement in hepatic steatosis have a significant favourable effect on the metabolic syndrome, including diabetes? / Jukka Westerbacka -- What are the dangers as well as the true benefits of bariatric surgery? / Andrew Jenkinson -- Liver transplantation : what can it offer? / Roger Williams -- Molecular antagonists, leptin or other hormones in supplementing environmental factors? / Jeremy Tomlinson -- Use of antifibrotic agents in clinical practice / Jonathan Fallowfield -- Better understanding of early development and material influence? / Jude Oben -- Defining the role of metabolic physician / Nicholas Finer. 410 0$aClinical Dilemmas (UK) 606 $aFatty liver 606 $aLiver$xDiseases 615 0$aFatty liver. 615 0$aLiver$xDiseases. 676 $a616.3/62 702 $aWilliams$b Roger$f1931- 702 $aTaylor-Robinson$b Simon D. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830823403321 996 $aClinical dilemmas in non-alcoholic fatty liver disease$94028411 997 $aUNINA